Screener / SEC EDGAR /CIK 0001743881 /10-K filed Feb 24, 2026, compared with Feb 20, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

BridgeBio Pharma, Inc. BBIO

Compare with peers Embed
The 10-K against last year's

278 changes: 49 added, 44 removed, 182 reworded, 3 quiet changes

10-K Feb 24, 2026 vs Feb 20, 2025

10-K 0001743881-26-000009 (Feb 24, 2026) vs 10-K 0000950170-25-024119 (Feb 20, 2025)

Every paragraph, and how much of it changed

One bar per paragraph, in the order of the 10-K. Height and colour show the share of its words not in the closest paragraph a year earlier; the tallest bars are new paragraphs.

Risk Factors

545 paragraphs · 20 new · 110 reworded · 22 gone · 10-K Feb 24, 2026 against Feb 20, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 329 · 49% changed Every version of it
Disruptions at the FDA and other agencies agencies, including substantial leadership departures, personnel cuts, and policy changes, may also slow the time necessary for new drugs to be reviewed and/or approved, or for other actions to be taken, by relevant government agencies, which would adversely affect our business. If a prolonged government shutdown Changes and cuts in FDA staffing have been reported by some within the pharmaceutical industry as creating instances of delays in the FDA’s responsiveness or disruption to the operations of the FDA or other regulatory authorities occurs, it could significantly impact the ability of the FDA or such other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Similarly, a prolonged government shutdown or disruption to the operations of the USPTO could prevent the timely review of our patent applications, which could delay the issuance of any U.S. patents to which we might otherwise be entitled. Future government shutdowns and similar events could impact our in its ability to access the public markets and obtain necessary capital review IND submissions or applications, issue regulations or guidance, or implement or enforce regulatory requirements in order to properly capitalize and continue our operations. a timely fashion or at all.
Paragraph 212 · 47% changed Every version of it
The drug substance and drug product for certain of our product candidates are manufactured by single-source suppliers or CMOs under pursuant to development and manufacturing contracts and services and contracts, quality agreements and purchase orders. We do not currently have any other suppliers for the drug substance or drug product of these product candidates and, although we believe that there are alternate sources of supply that could satisfy our clinical and commercial requirements, we cannot assure you that identifying alternate sources and establishing relationships with such sources would not result in significant delay in the development of our product candidates.
Paragraph 162 · 44% changed Every version of it
On August 3, 2017, Congress passed the FDA Reauthorization Act of 2017 (“FDARA”). FDARA, among other things, codified the FDA’s pre-existing regulatory interpretation to require that a sponsor demonstrate the clinical superiority of an orphan drug that is otherwise the same as a previously approved drug for the same rare disease in order to receive orphan drug exclusivity. The legislation reverses prior precedent holding that the Orphan Drug Act unambiguously requires that the FDA recognize the orphan exclusivity period regardless of a showing of clinical superiority. Moreover, in the Consolidated Appropriations Act of 2021, Congress did not further change this interpretation when it clarified that the interpretation codified in FDARA would apply in cases where FDA issued an orphan designation before the enactment of FDARA but where product approval came after the enactment of FDARA. The FDA may further reevaluate the Orphan Drug Act and its regulations and policies. We do not know if, when, or how the FDA may change the orphan drug regulations and policies in the future, and it is uncertain how any changes might affect our business. Depending on what changes the FDA may make to its orphan drug regulations and policies, our business could be adversely impacted.
Paragraph 367 · 44% changed Every version of it
Issues in the development and use of artificial intelligence, intelligence (AI), combined with an uncertain regulatory environment, may result in reputational harm, liability, or other adverse consequences to our business operations. As with many technological innovations, artificial intelligence AI presents risks and challenges that could impact our business. The use of certain artificial intelligence AI technology can give rise to intellectual property risks, including compromises to proprietary intellectual property and intellectual property infringement. Additionally, we expect to see increasing government and supranational regulation related to AI is evolving and could increase the burden and cost of compliance, including through requirements related to transparency, accountability, risk management, human oversight, and data governance. For example, the EU’s Artificial Intelligence Act (“AI Act”) — the world’s first comprehensive AI law — has entered into force on August 1, 2024, with additional provisions becoming effective on August 2, 2026. As currently enacted, this legislation, which may be amended as part of the EU’s Digital Omnibus, imposes significant obligations on providers and deployers of high-risk artificial intelligence systems, and encourages providers and deployers of artificial intelligence systems to account for EU ethical principles in their development and use of these systems. The scope of requirements depends on legal and ethics, which may risk determinations that rely on novel legal provisions that have not yet been interpreted by courts or regulators, and non-compliance can lead to significant fines.
Paragraph 524 · 42% changed Every version of it
We operate globally and plan to sell our products in countries throughout the world. Significant political, trade, or regulatory developments in the jurisdictions in which we sell our products, such as those stemming from the change in the U.S. federal administration, are difficult to predict and may have a material adverse effect on us. Similarly, changes in U.S. federal policy that affect the geopolitical landscape could give rise to circumstances outside our control that could have negative impacts on our business operations. For example, on February 1, in April 2025, the U.S. United States imposed a 25% tariff “reciprocal” tariffs, which were broad tariffs on imports from Canada and Mexico, which were subsequently suspended for a period of one month, and a 10% additional tariff virtually all countries, with particularly high tariffs on imports from China. The U.S. Supreme Court invalidated the reciprocal tariffs on February 20, 2026; however, President Trump has stated that he intends to use other authorities to maintain historically elevated tariffs. In response to higher U.S. tariffs, some countries have implemented retaliatory tariffs on U.S. goods, while others have negotiated agreements regarding U.S.-imposed tariffs. Historically, increased tariffs have led to increased more trade and political tensions and the status of these agreements between the United States and the various countries, in light of the U.S. Supreme Court’s February 20, 2026 decision, is not yet clear. Moreover, the United States has threatened to impose special tariffs on certain imported pharmaceutical products, which could take effect with minimal public notice. Political tensions as a result of trade policies could reduce trade volume, investment, technological exchange and other economic activities between major international economies, resulting in a material adverse effect on global economic conditions and the stability of global financial markets. Any changes in political, trade, regulatory, and economic conditions, including U.S. trade policies, could have a material adverse effect on our financial condition or results of operations.
Paragraph 330 · 39% changed Every version of it
Disruptions at Similar consequences would also result in the event of another significant shutdown of the federal government. For example, over the last several years, the U.S. government has shut down several times, including the most recent shutdown that began on October 1, 2025, and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved, or for other actions to be taken, by relevant government agencies, which would adversely affect our business. stop critical activities. If a prolonged government shutdown occurs, or disruption to the operations of if geopolitical or global health concerns prevent the FDA or other regulatory authorities occurs, from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or such other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business. business, including INDs placed on clinical holds or delayed new drug approvals. Similarly, a prolonged government shutdown or disruption to the operations of the USPTO could prevent the timely review of our patent applications, which could delay the issuance of any U.S. patents to which we might otherwise be entitled. Future Further, in our operations as a public company, future government shutdowns or substantial leadership, personnel, and similar events policy changes could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations. If the FDA is constrained in its ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted.
Paragraph 418 · 38% changed Every version of it
The Funding Agreement contains certain conditions We are parties to the Purchasers’ funding obligations Royalty Purchase Agreement and various the Funding Agreement, which contain certain covenants and restrictions on our operations that, if violated, may adversely affect our financial condition and operating results. An The Royalty Purchase Agreement requires us to direct 60% of BridgeBio’s European royalties on the first $500.0 million of annual BEYONTTRA net sales to the purchasers until the applicable cap is reached. Under the Funding Agreement, an increase in the rate of royalty interest payments payable by us to the royalty rate purchasers based on the net sales of Attruby under the Funding Agreement could harm impact our financial condition and operating results.
Paragraph 417 · 38% changed Every version of it
In the event the conditional conversion feature of the Notes is triggered, holders of the Notes will be entitled to convert the notes at any time during specified periods at their option. If one or more holders elect to convert their Notes, unless we elect to may satisfy our conversion obligation by delivering solely obligation, at our election, in cash, shares of our common stock, or a combination of cash and shares of our common stock (other than paying cash in lieu of delivering any fractional share), share). To the extent we would be required elect to settle any conversion in cash or in a combination of cash and shares, the cash portion or all of our conversion obligation through the payment of cash, which such settlement could adversely affect reduce our liquidity. In addition, even if holders do not elect to convert their Notes, we could be required For example, the 2027 and 2031 Notes became convertible for a limited period starting on January 1, 2026 under applicable accounting rules to reclassify all or a portion of the outstanding principal of the Notes as a current rather than long-term liability, which would result in a material reduction of our net working capital. conversion condition met and will remain convertible until March 31, 2026.

MD&A

168 paragraphs · 29 new · 107 reworded · 22 gone · 10-K Feb 24, 2026 against Feb 20, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 74 · 49% changed
As of December 31, 2024, 2025, we had net operating losses of approximately $1.4 billion and $439.4 million for federal and state income tax purposes, respectively, available to reduce future taxable income, if any. The federal net operating losses generated prior to 2018 in the amount of $10.8 million will begin to expire in 2036 and losses generated after 2018 in the amount of $1.4 billion will carry over indefinitely and would be subject to an 80% taxable income limitation in the year utilized. State net operating losses will generally begin to expire in 2036. We also have foreign net operating loss carryforwards of $404.5 million available to reduce future taxable income, if any, which will begin to expire in 2030. As of December 31, 2024, we had federal research and development and orphan drug credit carryforwards of $120.3 approximately $141.3 million, which will expire beginning in 2038 if not utilized. As of December 31, 2024, we had state research and development credit carryforwards of $29.1 million. The state research and development tax credits will expire at various dates while the California research and development tax credits will carry over indefinitely.
Paragraph 29 · 48% changed
Year Years Ended December 31, 2025 2024 2023 Change (in thousands) Research Cost of goods sold $15,687 $1,442 $14,245 Cost of license, services, and development $ 506,461 $455,711 $50,750 royalty revenue 5,275 2,436 2,839 Total cost of revenues $20,962 $3,878 $17,084
Paragraph 53 · 47% changed
Interest Noncash interest expense consists primarily of interest expense incurred under our 2029 Notes issued in January 2021, our 2027 Notes issued in March 2020, our term loan under the Amended Financing Agreement, our term loan under the Amended Loan Agreement, and accreted on our deferred royalty obligation obligations, net under the Funding Agreement and Royalty Purchase Agreement. Refer to Note 10 to our consolidated financial statements.
Paragraph 75 · 46% changed
As of December 31, 2024, 2025, we had net operating losses of approximately $1.4 billion have California and $439.4 million for federal and state income tax purposes, respectively, available to reduce future taxable income, if any. The federal net operating losses generated prior to 2018 in the amount of $10.8 million will begin to expire in 2036 and losses generated after 2018 in the amount of $1.4 billion will carry over indefinitely and would be subject to an 80% taxable income limitation in the year utilized. State net operating losses will generally begin to expire in 2036. We also have foreign net operating loss carryforwards of $404.5 million available to reduce future taxable income, if any, which will begin to expire in 2030. As of December 31, 2024, we had federal research and development and orphan drug credit carryforwards of $120.3 million, which will expire beginning in 2038 if not utilized. As of December 31, 2024, we had other state research and development tax credit carryforwards of $29.1 $37.4 million. The state research and development tax credits will expire at various dates while the California research and development tax credits will carry over indefinitely.
Paragraph 8 · 46% changed
In On January 2021, 21, 2026, we issued an aggregate of $632.5 million principal amount of $747.5 million of our 2029 Notes, 0.75% Convertible Senior Notes due 2033 (the “2033 Notes”), pursuant to an Indenture dated January 28, 2021 21, 2026 (the “2029 “2033 Notes Indenture”), between us and U.S. Bank Trust Company, National Association, as trustee (the “2029 “2033 Notes Trustee”), in a private offering to qualified institutional buyers (the “2021 “2026 Note Offering”), Offering”) pursuant to Rule 144A under the Securities Act. Act of 1933, as amended (the “Securities Act”). The 2033 Notes issued in the 2026 Note Offering include $82.5 million aggregate principal amount of the 2033 Notes sold to the initial purchasers of the 2033 Notes (the “2033 Notes Initial Purchasers”) pursuant to the exercise in full of the 2033 Notes Initial Purchasers’ option to purchase additional 2033 Notes. We received net proceeds from the 2026 Note Offering of approximately $619.3 million, after deducting the 2033 Notes Initial Purchasers’ discount and offering costs. We used approximately $82.5 million of the net proceeds from the 2026 Note Offering to pay for the repurchase of 1,081,825 shares of BridgeBio’s common stock. We intend to use the remainder of the net proceeds from the 2026 Note Offering to settle future conversion obligations in respect of or repay at maturity a portion of our 2.50% Convertible Senior Notes due 2027 (the “2027 Notes”), on or before the maturity date of the 2027 Notes and for general corporate purposes, which may include working capital, capital expenditures and/or debt repayment.
Paragraph 72 · 46% changed
As of December 31, 2024, 2025, we had net operating losses of approximately $1.4 billion and $439.4 million for federal and state income tax purposes, respectively, available to reduce future taxable income, if any. The federal net operating losses generated prior to 2018 in the amount of $10.8 million will begin to expire in 2036 and losses generated after 2018 in the amount of $1.4 billion will carry over indefinitely and would be subject to an 80% taxable income limitation in the year utilized. State net operating losses will generally begin to expire in 2036. We also have foreign net operating loss carryforwards of $404.5 million available to reduce future taxable income, if any, which will begin to expire in 2030. As for federal and state income tax purposes of December 31, 2024, we had federal research approximately $1.7 billion and development and orphan drug credit carryforwards of $120.3 $462.2 million, which will expire beginning in 2038 if not utilized. As of December 31, 2024, we had state research and development credit carryforwards of $29.1 million. The state research and development tax credits will expire at various dates while the California research and development tax credits will carry over indefinitely. respectively.
Paragraph 41 · 46% changed
Selling, general and administrative expenses increased by $138.3 $242.3 million in 2024 for the year ended December 31, 2025, compared to 2023, mainly 2024. The increase was primarily driven by a $132.9 million increase in external costs and a $88.6 million increase in personnel-related expenses, largely due to an increase in personnel related expense activities supporting our commercial launch and ongoing activities of $56.1 Attruby, as well as a $20.8 million and external costs of $55.2 million to support our commercialization readiness efforts, which included costs incurred for marketing, advertising and hiring of a sales force for the U.S.; nonrecurring deal-related expenses of $16.5 million; and an increase in stock-based compensation expense of $10.5 million. expenses.
Paragraph 26 · 45% changed
Revenue increased by $212.6 million in 2024 in comparison License and services revenue decreased for the year ended December 31, 2025, compared to 2023. Revenue for 2024 2024, primarily consisted due to recognition of $207.7 million from the recognition of the upfront license fee fees and services revenue recognized in 2024 under the Bayer License Agreement and the KKC Agreement; net product revenue from the commercial sale of Attruby in the U.S. of $2.9 million; License Agreement. License and $9.9 million attributable to the remaining services revenue in connection with the Navire-BMS License Agreement as a result of the termination of the agreement. Revenue for 2023 2025 primarily consisted of $105.0 million recognized for milestone achievements following approval of Beyonttra in the recognition EU and pricing approval of Beyonttra in Japan. The remaining change in license and services revenue under is primarily driven by service revenue recognized on the Navire-BMS License Agreement non-refundable upfront payments received in 2024 and license revenue for from the shipment sale of clinical supplies and commercial product supply to our partners pursuant to our executed supply agreements and services revenue. collaboration partners.

A paragraph is matched with the one last year that shares the most of its words; under half in common makes it new. The paragraphs shown are the 8 reworded the most in each section.

The paragraph that changed most in each section

The redline

Marked against last year's 10-K: cut words struck through, new words highlighted.

Risk Factors342 words changed in this paragraph; it is 35% similar to last year's version.
There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at containing or lowering the cost of healthcare. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize Attruby and Beyonttra and our other product candidates, if approved. Such reforms could have an adverse effect on anticipated revenue from product candidates that we may successfully develop and for which we may obtain regulatory approval and may affect our overall financial condition and ability to develop product candidates. For example, the current administration is pursuing a two-fold strategy to reduce drug costs in the United States. While it is unclear whether and how the current administration’s proposals will be implemented, these policies are likely to have a negative impact on the pharmaceutical industry and on our ability to receive adequate revenues for our products. The current administration has threatened to impose significant tariffs on pharmaceutical manufacturers that do not adopt pricing policies such as most-favored-nation pricing, which would tie the price for drugs in the United States to the lowest price in a group of other countries. While the United States has not implemented these tariffs, the United States could impose them with minimal notice to the public. In response, multiple manufacturers have entered into confidential pricing agreements with the federal government. On the other hand, the current administration is pursuing traditional regulatory pathways to impose drug pricing policies and published two proposed regulations in December 2025, referred to as GLOBE and GUARD. If finalized, these regulations would implement mandatory payment models under which manufacturers of eligible drugs would be required to pay rebates to the federal government on a portion of the units of their drugs that are reimbursed by Medicare, with the rebate amount based on most-favored-nation pricing. Imposing a rebate in the United States that is based on drug prices outside the United States would mark a drastic and unprecedented shift in the U.S. pharmaceutical market, and while the impact of the GLOBE and GUARD proposed regulations, if finalized, cannot yet be determined, it is likely to be significant depending on the final language. Even regulatory proposals or executive actions that are ultimately deemed unlawful could negatively impact the U.S. pharmaceutical sector and our business. We cannot predict the initiatives that may be adopted in the future. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect:

Source: Item 1A, 10-K 0001743881-26-000009 vs Item 1A, 10-K 0000950170-25-024119

Accounting Policies267 words changed in this paragraph; it is 33% similar to last year's version.
Cost Inventory is recorded at the lower of revenue consists cost or net realizable value. The cost of manufacturing costs, transportation raw materials, work in process and freight, finished goods are determined using a standard cost approach, which approximates actual cost determined on a first-in, first-out basis. Raw and indirect overhead intermediate materials that may be used for either research and development or commercial purposes are classified as inventory until the material is consumed or otherwise allocated for research and development. If the material is used for research and development, it is expensed as research and development once that determination is made. We capitalize inventory costs (including salary related and stock-based compensation expenses) associated with that are expected to be sold commercially once we determine it is probable that the inventory costs will be recovered through commercial manufacturing and distribution of Attruby, third-party royalties payable on our net product revenues. Cost of revenue also consists of amortization of intangible assets associated with the sale of our products, which are amortized over the life of the underlying intellectual property. Cost of revenue may also include period costs related to excess or obsolete inventory adjustment charges, abnormal costs, unabsorbed manufacturing and overhead costs, and manufacturing variances. sales. Prior to regulatory approval of our product candidates, we recorded record costs related to manufacturing and materials as “Research and development expenses” development” expenses in the period incurred on the consolidated statements of operations, and therefore such costs are not included in cost of revenue. revenues. Subsequent to the FDA approval of Attruby in November 2024, these the costs directly related costs for to Attruby manufacturing were capitalized as inventory. We periodically review inventories to identify excess, dated, or obsolete inventory costs and recognized in our record reserves and write-downs as necessary to reflect inventories at net realizable value. Provision for inventory reserves and write-downs are recorded within “Cost of revenues” on the consolidated statements of operations as cost of revenue upon sale of our product. operations.

Source: Item 8, Note 2 – Summary of Significant Accounting Policies, 10-K 0001743881-26-000009 vs Item 8, Note 2 – Summary of Significant Accounting Policies, 10-K 0000950170-25-024119

MD&A245 words changed in this paragraph; it is 51% similar to last year's version.
Net cash used in operating activities was $520.7 $445.9 million in 2024, consisting primarily for the year ended December 31, 2025 and consisted of our net loss of $543.3 million; adjusted $732.9 million, adjustments for non-cash noncash items totaling $9.4 $338.1 million, which and net cash outflow of $51.1 million related to changes in operating assets and liabilities. The adjustments for noncash items totaling $338.1 million primarily includes a gain of $178.3 million from the deconsolidation of subsidiaries, a net gain of $8.1 million from investment in equity securities, and offset by $95.8 included $133.0 million in stock-based compensation expense, $31.2 $125.1 million in noncash interest expense on deferred royalty obligations, $72.6 million in net loss from equity method investments, $26.6 $21.2 million in loss on extinguishment extinguishments of debt from the repayment of the term loan under the Amended Loan Financing Agreement, $15.8 $6.0 million in accretion amortization of debt, $6.1 debt discount and issuance costs, and $5.4 million in depreciation and amortization; partially offset by $19.7 million in change in fair value of the embedded derivative associated with the deferred royalty obligation under the Funding Agreement (as described in Note 10 of our consolidated financial statements) and a $32.0 $8.8 million in noncash income from our equity method investments. The net cash inflow related to changes in operating assets and liabilities. The $32.0 outflow of $51.1 million net cash inflow related to changes in operating assets and liabilities was attributed mainly to an increase of $134.7 million in accounts receivable, net primarily related to receivables for net product revenues, an increase of $25.3 million in inventories due to a continuing build-up of Attruby inventory following its commercialization in November 2024, an increase of $8.8 million in prepaid expenses and other current assets primarily due to timing of payments and fluctuations in our operations, and a decrease of $11.4 million in deferred revenue of $21.9 million primarily related to the Bayer License Agreement and KKC Agreement, License Agreement; partially offset by an increase of $17.0 $26.6 million in accounts payable, an increase of $23.0 million in accrued compensation and benefits, and an increase of $8.7 $77.8 million in accrued research and development other liabilities, partially offset by a decrease in prepaid expenses and other current assets of $13.9 million, which are collectively primarily due to timing of payments.

Source: Item 7, 10-K 0001743881-26-000009 vs Item 7, 10-K 0000950170-25-024119

Legal Proceedings87 words changed in this paragraph; it is 32% similar to last year's version.
We In the normal course of business, we have also entered into a contracts which contain minimum noncancellable purchase commitments and obligations. These include commitments for the supply, manufacturing, and packaging of our commercial supply agreement product as well as agreements to purchase active pharmaceutical ingredient (“API”), bulk drug product support the sales and packaging, marketing activities for which we have a minimum purchase commitment of $32.9 million as Attruby. As of December 31, 2024. In addition, 2025, we have entered into agreements to support our commercial launch of Attruby for which we have a minimum commitment noncancellable commitments in aggregate of $1.0 million as of December 31, 2024. $110.2 million.

Source: Item 3, via Note 8 – Commitments and Contingencies, 10-K 0001743881-26-000009 vs Item 3, via Note 8 – Commitments and Contingencies, 10-K 0000950170-25-024119

Sentences and paragraphs added, removed or reworded

Every change, by type

Sentences and paragraphs of BBIO's Risk Factors and MD&A, 10-K Feb 24, 2026 against 10-K Feb 20, 2025. Each links to the text at sec.gov.

Quiet changes are sentences kept from last year with one to four words changed, at least one of them a hedge, a modal or a qualifier (may, could, will, not, significant, material…). A year or date rolling forward is not counted.

The full word list

adverse, adversely, all, although, anticipate, anticipates, any, approximately, believe, believes, can, cannot, certain, could, expect, expects, generally, however, if, intend, intends, largely, likely, many, material, materially, may, might, most, must, never, no, not, possible, primarily, probable, should, significant, significantly, some, substantial, substantially, unlikely, will, would

AddedRisk Factors
There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at containing or lowering the cost of healthcare. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize Attruby and Beyonttra and our product candidates, if approved. Such reforms could have an adverse effect on anticipated revenue from product candidates that we may successfully develop and for which we may obtain regulatory approval and may affect our overall financial condition and ability to develop product candidates. For example, the current administration is pursuing a two-fold strategy to reduce drug costs in the United States. While it is unclear whether and how the current administration’s proposals will be implemented, these policies are likely to have a negative impact on the pharmaceutical industry and on our ability to receive adequate revenues for our products. The current administration has threatened to impose significant tariffs on pharmaceutical manufacturers that do not adopt pricing policies such as most-favored-nation pricing, which would tie the price for drugs in the United States to the lowest price in a group of other countries. While the United States has not implemented these tariffs, the United States could impose them with minimal notice to the public. In response, multiple manufacturers have entered into confidential pricing agreements with the federal government. On the other hand, the current administration is pursuing traditional regulatory pathways to impose drug pricing policies and published two proposed regulations in December 2025, referred to as GLOBE and GUARD. If finalized, these regulations would implement mandatory payment models under which manufacturers of eligible drugs would be required to pay rebates to the federal government on a portion of the units of their drugs that are reimbursed by Medicare, with the rebate amount based on most-favored-nation pricing. Imposing a rebate in the United States that is based on drug prices outside the United States would mark a drastic and unprecedented shift in the U.S. pharmaceutical market, and while the impact of the GLOBE and GUARD proposed regulations, if finalized, cannot yet be determined, it is likely to be significant depending on the final language. Even regulatory proposals or executive actions that are ultimately deemed unlawful could negatively impact the U.S. pharmaceutical sector and our business. We cannot predict the initiatives that may be adopted in the future. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect:
Read it in 10-K Feb 24, 2026 at sec.gov
AddedRisk Factors
Federal legislative and regulatory efforts to implement reference pricing or most-favored-nation pricing models could impact our product revenues and materially harm our business.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedRisk Factors
On May 12, 2025, the current administration issued an executive order calling on pharmaceutical manufacturers to voluntarily reduce the prices of medicines in the U.S. and directing the Secretary of Health and Human Services (HHS) to communicate most-favored-nation (MFN) price targets to pharmaceutical manufacturers to align prices with those in comparably developed nations and, in the event significant progress towards MFN pricing is not delivered, to propose rulemaking to impose MFN pricing.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedRisk Factors
Since the May 12, 2025 order, the current administration has continued to exert pressure on drug manufacturers to implement MFN pricing, including by suggesting that the administration may impose significant tariffs on pharmaceuticals if such manufacturers do not reach agreements to implement MFN pricing. Further, in November 2025, the Centers for Medicare & Medicaid Services (“CMS”) introduced the GENEROUS (GENErating cost Reductions fOr U.S. Medicaid) Model, a voluntary Medicaid payment initiative under which participating drug manufacturers may voluntarily offer supplemental rebates to participating state Medicaid programs that are intended to provide such Medicaid programs with an MFN price for the manufacturers’ products. Additionally, in December 2025, CMS announced proposals for new mandatory demonstration payment models through two proposed rules under its Center for Medicare and Medicaid Innovation (“CMMI”) authority, the Global Benchmark for Efficient Drug Pricing (“GLOBE”) for Medicare Part B and Guarding U.S. Medicare Against Rising Drug Costs (“GUARD”) for Medicare Part D. If finalized, these models would impose additional mandatory rebates on manufacturers of certain Medicare Part B and Medicare Part D drugs, for select Medicare populations intended to represent 25% of Medicare patients, if the Medicare prices for such products exceed those paid in economically comparable countries. Both the GLOBE and GUARD models have proposed seven-year testing periods, with the GLOBE model proposed to begin on October 1, 2026 and the GUARD model proposed to begin on January 1, 2027.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedRisk Factors
If the GLOBE and GUARD models are finalized as proposed under CMMI authority, we could be required to pay additional rebates on products reimbursed by Medicare for the covered populations during the applicable model periods. In addition, if MFN pricing or similar reference pricing policies are enacted or implemented in the U.S. outside of the CMMI framework and applied more broadly, we could be required to pay rebates on products utilization by a broader portion of U.S. patients to align with prices in certain reference countries. We currently derive the substantial portion of our revenue from U.S. sales, and any requirement to pay additional rebates in the U.S. to match international reference prices would impact our overall net product revenue.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedRisk Factors
MFN pricing models in the U.S. could also affect our international pricing strategy and future decisions on reimbursement and commercialization in certain jurisdictions. If our U.S. pricing becomes tied to international reference prices, especially in light of our licensing agreements with Bayer and Alexion, we may face decisions regarding pricing in foreign markets that could result in reduced patient access internationally, affect our relationships with foreign regulatory authorities and payers, or impact our ability to obtain or maintain reimbursement approvals in ex-U.S. markets. These reforms remain subject to change, potential legal challenges, or expansion through additional rulemaking or sub regulatory guidance, creating uncertainty for our overall pricing strategy. It remains to be seen whether and how these drug pricing initiatives will apply to our products, how they will affect the broader pharmaceutical industry, and whether similar reform measures may be adopted in the future.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedRisk Factors
On February 3, 2026, Congress passed the Consolidated Appropriations Act of 2026. The RARE Act codified the FDA’s longstanding regulatory interpretation that orphan drug exclusivity applies only to the specific approved use or indication of a drug or biological product, rather than to all uses within a designated rare disease or condition.
Read it in 10-K Feb 24, 2026 at sec.gov
Show the other 67
AddedRisk Factors
The Consolidated Appropriations Act of 2026 reauthorized the FDA’s authority to award priority review vouchers to sponsors of new products intended to treat rare pediatric diseases through September 30, 2029. Under current law, after September 30, 2029, the FDA may not award any rare pediatric disease priority review vouchers, although the FDA’s authority to do so could be extended by Congress in the future.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedRisk Factors
In September 2025, the FDA announced increased scrutiny of advertising and promotional practices, with a particular focus on direct-to-consumer (“DTC”) advertising and reportedly sent thousands of letters to pharmaceutical companies to remove misleading ads, including a large number of untitled and warning letters citing allegedly misleading claims. For example, we received one of these untitled letters citing a DTC broadcast advertisement for Attruby. This heightened enforcement environment increases the risk that our promotional materials, even if we believe them to be compliant, could be challenged by the FDA or by consumers or plaintiffs’ counsel, which could lead us to modify or withdraw certain promotional materials. If we cannot successfully manage the promotion of our products or product candidates, if approved, we could become subject to significant liability, which would materially adversely affect our business and financial condition.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedRisk Factors
The drug product for Attruby and Beyonttra is currently supplied by one primary supplier. Although we have entered into a master agreement with an alternative supplier of drug product for this commercial product and expect the initial commercial batch of this material to be released to us later this year from this secondary supplier, we may encounter unexpected delays in the manufacture and supply of commercial drug product.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedRisk Factors
With the change in the U.S. Presidential Administration in 2025, there continues to be substantial uncertainty as to whether and how the current administration will seek to modify or revise the requirements and policies of the FDA and other regulatory agencies with jurisdiction over our product candidates and any products for which we obtain approval. This uncertainty could present new challenges as we navigate development and approval of our product candidates. Some of these efforts have manifested to date in the form of personnel cuts and measures that could impact the FDA’s ability to hire and retain key personnel, which could result in delays or limitations on our ability to obtain guidance from the FDA on our product candidates in development and obtain the requisite regulatory approvals in the future. There remains general uncertainty regarding future activities. The current administration could issue or promulgate executive orders, regulations, policies or guidance that adversely affect us or create a more challenging or costly environment to pursue the development of new therapeutic products. Alternatively, state governments may attempt to address or react to changes at the federal level with changes to their own regulatory frameworks in a manner that is adverse to our operations. If we become negatively impacted by future governmental orders, regulations, policies or guidance as a result of the current Administration, there could be a material adverse effect on us and our business.
Read it in 10-K Feb 24, 2026 at sec.gov
RemovedRisk Factors
There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at containing or lowering the cost of healthcare. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or
Read it in 10-K Feb 20, 2025 at sec.gov
RemovedRisk Factors
commercialize Attruby and Beyonttra and our other product candidates, if approved. Such reforms could have an adverse effect on anticipated revenue from product candidates that we may successfully develop and for which we may obtain regulatory approval and may affect our overall financial condition and ability to develop product candidates. We cannot predict the initiatives that may be adopted in the future. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect:
Read it in 10-K Feb 20, 2025 at sec.gov
RemovedRisk Factors
The FDA’s rare pediatric disease priority voucher program began to sunset on December 20, 2024, on failure to pass a continuing resolution package that included its reauthorization. Under the amended statutory sunset provisions, after December 20, 2024, the FDA may award a PRV for an approved rare pediatric disease product application only if the sponsor has rare pediatric disease designation for the drug and if that designation was granted by December 20, 2024. After September 30, 2026, the FDA may not award any rare pediatric disease PRVs. Congress may vote to reauthorize this program, but its future remains unknown at this time. Absent such legislative reauthorization of the program, if an NDA for BBP-812 is not approved prior to September 30, 2026 for any reason, regardless of whether it meets the criteria for a rare pediatric disease PRV, it will not be eligible for a PRV.
Read it in 10-K Feb 20, 2025 at sec.gov
RemovedRisk Factors
We may seek designation for our platform technology as a designated platform technology. A sponsor may request the FDA to designate a platform technology as a designated platform technology concurrently with, or at any time after, submission of an IND application for a drug that incorporates or utilizes the platform technology that is the subject of the request. If so designated, the FDA may expedite the development and review of any subsequent original NDA or BLA for a drug that uses or incorporates the platform technology. Even if we believe our platform technology meets the criteria for such designation, the FDA may disagree and instead determine not to grant such designation. In addition, the receipt of such designation for a platform technology does not ensure that a drug will be developed more quickly or receive a faster FDA review process or ultimate FDA approval. Moreover, the FDA may revoke a designation if the FDA determines that a designated platform technology no longer meets the criteria for such designation. See the section titled, “Business — Government Regulation — Expedited Development and Review Programs.”
Read it in 10-K Feb 20, 2025 at sec.gov
RemovedRisk Factors
Manufacturers and manufacturers’ facilities are required to comply with extensive requirements imposed by the FDA and comparable foreign regulatory authorities, including ensuring that quality control and manufacturing
Read it in 10-K Feb 20, 2025 at sec.gov
RemovedRisk Factors
If we or one of our licensing partners initiated legal proceedings against a third party to enforce a patent covering one or more of our product candidates, the defendant could counterclaim that the patent covering the relevant product candidate is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could
Read it in 10-K Feb 20, 2025 at sec.gov
RemovedRisk Factors
Inflation and rapid increases in interest rates have led to a decline in the trading value of previously issued government securities with interest rates below current market interest rates. Although the U.S. Department of Treasury, FDIC and Federal Reserve Board have announced a program to provide up to $25 billion of loans to financial institutions secured by certain of such government securities held by financial institutions to mitigate the risk of potential losses on the sale of such instruments, widespread demands for customer withdrawals or other liquidity needs of financial institutions for immediate liquidity may exceed the capacity of such program. Additionally, there is no guarantee that the U.S. Department of Treasury, FDIC and Federal Reserve Board will provide access to uninsured funds in the future in the event of the closure of other banks or financial institutions, or that they would do so in a timely fashion.
Read it in 10-K Feb 20, 2025 at sec.gov
RemovedRisk Factors
Although the EU GDPR and the UK GDPR currently impose substantially similar obligations, it is possible that over time the UK GDPR could become less aligned with the EU GDPR, particularly with the introduction of the
Read it in 10-K Feb 20, 2025 at sec.gov
RemovedRisk Factors
We have incurred indebtedness under our convertible senior notes and are party to a financing agreement that contains operating and financial covenants that may restrict our business and financing activities.
Read it in 10-K Feb 20, 2025 at sec.gov
RewordedRisk Factors
Inadequate funding for Disruptions to the operations of the FDA, the SEC and other government agencies, including from government shut downs, or other disruptions comparable regulatory authorities caused by funding shortages or global health concerns, in addition to substantial uncertainty regarding the current Administration’s initiatives and staffing cuts and how these agencies’ operations, might impact the FDA, its implementation of laws, regulations, policies and guidance, and its personnel, could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, including timely reviews, which could negatively impact our business.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
If one or more holders elect to convert their Notes, unless we elect to may satisfy our conversion obligation by delivering solely obligation, at our election, in cash, shares of our common stock, or a combination of cash and shares of our common stock (other than paying cash in lieu of delivering any fractional share), we would be required to settle a portion or all of our conversion obligation through the payment of cash, which could adversely affect our liquidity. share).
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
We do not currently have any other suppliers for the drug substance or drug product of for these product candidates and, although we believe that there are alternate sources of supply that could satisfy our clinical requirements and commercial requirements, are in the process of establishing agreements with alternate suppliers, we cannot assure you that we will be successful in identifying alternate sources and establishing relationships with such sources would not result in sources, or that we will be able to avoid significant delay delays or disruptions in the development of our product candidates. candidates due to our current reliance on single-source suppliers.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
We may also fail to obtain or maintain the necessary regulatory approvals, distribution licenses or other registrations that are required to ship an approved product to a customer or commercial partner. partner, or our contract manufacturers may fail to supply us or our commercial partners with our required or forecasted amounts of finished product, active pharmaceutical ingredients or raw materials to meet commercial demand on a timely basis, or at all.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
Our vendors may also in turn incorporate generative artificial intelligence AI tools into their offerings without disclosing this use to us, offerings, and the providers of these generative artificial intelligence AI tools may not meet existing or rapidly evolving regulatory or industry standards standards, including with respect to privacy and data protection and may inhibit our or our vendors’ ability to maintain an adequate level of service and experience. security.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
If a prolonged government shutdown occurs, or disruption to the operations of if geopolitical or global health concerns prevent the FDA or other regulatory authorities occurs, from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or such other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business. business, including INDs placed on clinical holds or delayed new drug approvals.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
If the Seller Parties we are unable to comply with applicable obligations, the Purchasers purchasers under the Royalty Purchase Agreement or the Funding Agreement, as applicable, may be entitled to take exercise remedies against their respective collateral securing our obligations, including taking possession of such assets, assets under the Funding Agreement, which could have a material adverse effect on our business, financial condition and results of operations.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
We could also encounter delays if an ongoing or planned clinical trial is suspended or terminated by us, by the data safety monitoring board (“DSMB”) including for our ongoing Phase 3 clinical trial of low-dose infigratinib, our ongoing Phase 2 and planned Phase 3 clinical trials of BBP-418, and our ongoing Phase 3 clinical trial of encaleret, (“DSMB”), or by the FDA or other regulatory authority, or if the IRBs of the institutions in which such trials are being conducted suspend or terminate the participation of their clinical investigators and sites subject to their review.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
Our We have recorded significant restructuring charges from our corporate restructuring initiatives, including any associated workforce reductions or reorganizations, and may do so again in the future, which could have a material negative impact on our results of operations, may not result in the full anticipated savings savings, and may disrupt operations.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
Under For example, under the Funding Agreement, the Seller Parties we are required to comply with various covenants, including using use commercially reasonable efforts to obtain regulatory approval for and commercialize Attruby, providing provide the Funding Agreement Purchasers with certain clinical, commercial, regulatory and intellectual property updates and certain financial statements, and providing provide notices upon the occurrence of certain events, each as agreed under the Funding Agreement. events.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
Our business is substantially dependent on our ability to successfully commercialize AttrubyTM and BeyonttraTM, and the The continued commercial success of Attruby and Beyonttra or any other this product, along with our product candidates, if approved, will depend upon the degree of market acceptance by physicians, patients, healthcare payors, and others in the medical community.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedRisk Factors
Actual events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past past, such as in the case of the closure and subsequent placement into receivership with the Federal Deposit Insurance Corporation (“FDIC”) of Silicon Valley Bank in March 2023, and may in the future lead to market-wide liquidity problems.
Read it in 10-K Feb 24, 2026 at sec.gov
Quiet changesRisk Factors
In addition, if we are required to change CMOs for any reason, we will be required to verify that the new CMO maintains facilities and procedures that comply with quality standards and with all applicable regulations.
Read it in 10-K Feb 24, 2026 at sec.gov
Quiet changesRisk Factors
While new AAV vectors have been developed to reduce some of these side effects, gene therapy is still a relatively new approach to disease treatment and additional adverse side effects could develop.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
BridgeBio Pharma, Inc. (“BridgeBio,” the “Company,” or “we”), is a commercial-stage, multi-product biopharmaceutical company organized around a portfolio operating model to discover, develop, and deliver medicines for patients with genetic diseases. We seek to translate advances in genetic science into therapies for patient populations with significant unmet medical needs.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
On June 27, 2025 (the “Closing Date”), we and our subsidiary, Eidos Therapeutics, Inc. (“Eidos”), entered into a Royalty Interest Purchase and Sale Agreement (the “Royalty Purchase Agreement”) with Acoramidis Royalty SPV, LP (“ARS”), an affiliate of HealthCare Royalty Management, LLC (“HCRx”), as a purchaser and the purchaser representative (in such capacity, the “Purchaser Representative”), and LSI Financing Fund, LP, an affiliate of Blue Owl Capital Corporation, as a purchaser (together with ARS as a purchaser and any future permitted assignees of a purchaser, the “Royalty Agreement Purchasers”). Subsequent to the Closing Date, on July 30, 2025, KKR & Co. Inc., a beneficial holder of our common equity and a related party, acquired a majority ownership interest in HCRx. Accordingly, HCRx became our related party following KKR & Co. Inc.’s acquisition of HCRx.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
Pursuant to the Royalty Purchase Agreement, Eidos sold to the Royalty Agreement Purchasers certain of Eidos’ right to receive certain royalty payments (“Purchased Royalty Payment”) on net sales of certain products containing acoramidis (the “Licensed Products”) made in the European Union (“EU”) and all member and extension states of the European Patent Organization (the “Licensed Territory”) under (i) an exclusive license agreement, dated as of March 1, 2024, by and among Bayer Consumer Care AG (“Bayer”), Eidos and our other subsidiaries party thereto, as amended from time to time (the “Bayer License Agreement”) and (ii) an amended and restated license agreement, effective as of June 30, 2023, by and between Eidos and our other subsidiary, BridgeBio International GmbH. As consideration for the sale of the Purchased Royalty Payment, the Royalty Agreement Purchasers agreed to pay Eidos $300.0 million in cash (the “Purchase Price”), which was funded in full on the Closing Date. The Royalty Agreement Purchasers’ rights to the Purchased Royalty Payment are subject to (a) an annual cap equal to 60% of all royalty payments paid by Bayer to Eidos and its affiliates under the Bayer License Agreement on the first $500.0 million of annual net sales of Licensed Products in the Licensed Territory under the Bayer License Agreement and (b) an initial hard cap equal to 145% of the Purchase Price. Refer to Liquidity and Capital Resources section for additional details regarding this agreement.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
On January 17, 2024, we and our subsidiaries, Eidos, BridgeBio Europe B.V. and BridgeBio International GmbH (collectively, the “Seller Parties”), entered into a Funding Agreement (the “Funding Agreement”) with LSI Financing 1 Designated Activity Company and CPPIB Credit Europe S.à r.l. (together and with any future permitted assignees of a seller party, the “Funding Agreement Purchasers”), and Alter Domus (US) LLC, as the collateral agent. In connection with the Royalty Purchase Agreement described above, the Funding Agreement was amended on June 27, 2025. All terms and conditions of the Funding Agreement remain substantially unchanged. Refer to Liquidity and Capital Resources section for additional details regarding this agreement.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
Total revenues, net increased by $280.2 million for the year ended December 31, 2025, compared to 2024, which consisted of an increase of $359.5 million in net product revenue, a decrease of $90.5 million in license and services revenue, and an increase of $11.2 million in royalty revenue.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
Net product revenue for the year ended December 31, 2025 was $362.4 million. This revenue was generated from the commercial sale of Attruby in the U.S. following FDA approval in November 2024.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
Royalty revenue for the year ended December 31, 2025 was $11.4 million. This revenue primarily relates to royalties earned from net product sales of Beyonttra in the EU, following EC approval in February 2025, and in Japan, following pricing approval in May 2025.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
Total cost of revenues increased by $17.1 million for the year ended December 31, 2025, compared to 2024, primarily due to an increase of $14.3 million in cost of goods sold and an increase of $2.8 million in cost of license, services, and royalty revenue.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
Cost of goods sold for the years ended December 31, 2025 and 2024 consists of manufacturing costs, transportation and freight-in, and indirect overhead costs (including salary and benefits related and stock-based compensation expenses) associated with the commercial manufacturing and distribution of Attruby, and third-party royalties associated with our net product revenue. We began incurring cost of goods sold following FDA approval and commercial launch of Attruby in November 2024.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
Cost of license, services, and royalty revenue for the years ended December 31, 2025 and 2024, consists mainly of third-party royalties associated with commercial sales of Beyonttra, manufacturing costs relating to product supply of Beyonttra to our collaboration partners, and amortization of intangible assets for milestones achieved upon FDA approval from our license and collaboration agreements. We began incurring royalties and manufacturing costs associated with commercial sales of Beyonttra upon its approval in the EU, Japan, and the UK in 2025.
Read it in 10-K Feb 24, 2026 at sec.gov
AddedMD&A
Research and development expenses decreased by $54.5 million for the year ended December 31, 2025, compared to 2024. The decrease consisted of a $32.4 million decrease in external costs, a $9.4 million decrease in personnel-related expenses, and a $0.6 million decrease in stock-based compensation expenses, which are collectively primarily driven by decreased R&D activities related to the Attruby and Beyonttra program following regulatory approval and the reprioritization of our R&D programs. In addition, there was a $12.1 million decrease in license fees due to timing of milestones achieved.
Read it in 10-K Feb 24, 2026 at sec.gov
RemovedMD&A
BridgeBio Pharma, Inc. (“we” or the “Company”) is a new type of biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials.
Read it in 10-K Feb 20, 2025 at sec.gov
RemovedMD&A
GondolaBio was formed on June 5, 2024 and we were the sole member. On August 16, 2024, based on the recommendation of a special committee of independent and disinterested directors of BridgeBio, we entered into a
Read it in 10-K Feb 20, 2025 at sec.gov
RemovedMD&A
transaction agreement (the “Transaction Agreement”) providing for the formation and funding by certain third party investors of GondolaBio, LLC, a Delaware limited liability company (“GondolaBio”), a legal joint venture entity for the purpose of researching, developing, manufacturing and commercializing pharmaceutical products, including certain assets contributed to GondolaBio by BridgeBio. The investors providing financing to GondolaBio consist of an investor syndicate, including Viking Global Investors LP, Patient Square Capital, Sequoia Capital, Frazier Life Sciences, Cormorant Asset Management, Aisling Capital and an entity owned by Neil Kumar, the Company’s Chief Executive Officer. The investors have committed $300.0 million of tranched financing to GondolaBio, of which $60.0 million had been contributed during the period August 16, 2024 through December 31, 2024. We contributed certain assets and our equity in Portal Therapeutics, Inc. and Sub21, Inc. to GondolaBio. Upon completion of the initial contributions, the Company’s equity ownership in GondolaBio was 45.5%, which had a fair value of $50.0 million, and will be subject to reduction as additional tranches of capital contributions are funded. On August 16, 2024, in conjunction with the Transaction Agreement, GondolaBio’s limited liability company agreement was amended and restated to reflect a change in its governance structure and composition of the board of managers, which was determined to be a VIE reconsideration event. Based on the VIE reconsideration assessment, GondolaBio was deemed a VIE. As a result of the change in governance structure and composition of the board of managers, we are no longer the primary beneficiary, as we no longer have the power over key decisions that significantly impact GondolaBio’s economic performance. Accordingly, we deconsolidated GondolaBio, inclusive of Portal Therapeutics, Inc. and Sub21, Inc., on August 16, 2024. On August 16, 2024, we recognized an approximate $52.0 million net gain from deconsolidation of subsidiaries which is presented on the consolidated statements of operations for the year ended December 31, 2024. Upon the deconsolidation of GondolaBio on August 16, 2024, we accounted for our investment in GondolaBio, for which we had significant influence through our ownership interest, using the equity method of accounting. GondolaBio was also deemed a related party. For the period August 16, 2024 through December 31, 2024, we recognized a net loss from equity method investment of $8.5 million. As of December 31, 2024, the aggregate carrying amount of our equity method investment in GondolaBio is $41.5 million and is presented as part of “Investment in nonconsolidated entities” on our consolidated balance sheets.
Read it in 10-K Feb 20, 2025 at sec.gov
RemovedMD&A
On April 30, 2024, TheRas, Inc., doing business as BridgeBio Oncology Therapeutics (BBOT), a majority-owned subsidiary of the Company, completed a $200.0 million private equity financing with external investors to accelerate the development of its oncology portfolio. As part of the private equity financing transaction, BBOT’s Certificate of Incorporation and Investors’ Rights Agreement were amended and restated to reflect a change in BBOT’s governance structure and composition of the board of directors, which was determined to be a VIE reconsideration event. Based on the VIE reconsideration assessment, BBOT was deemed a VIE. As a result of the change in the governance structure and composition of the board of directors, we are no longer the primary beneficiary of BBOT, as we no longer have the power over key decisions that significantly impact BBOT’s economic performance. Accordingly, we deconsolidated BBOT on April 30, 2024. On April 30, 2024, we recognized a $126.3 million gain from deconsolidation of subsidiaries which is presented on the consolidated statements of operations for the year ended December 31, 2024. Upon the deconsolidation of BBOT, BridgeBio accounted for its retained investments in BBOT, for which it has significant influence through its ownership interest, using the equity method of accounting. BBOT was also deemed a related party. For the period from May 1, 2024 through December 31, 2024, we recognized a net loss from equity method investment of $22.7 million. As of December 31, 2024, the aggregate carrying amount of our equity method investment in BBOT is $102.2 million and is presented as part of “Investment in nonconsolidated entities” on our consolidated balance sheets.
Read it in 10-K Feb 20, 2025 at sec.gov
RemovedMD&A
Supply Agreement with an initial 30-month term ending in December 2026, for which BridgeBio B.V. will manufacture and supply to Bayer the commercial product ordered by Bayer solely for the use in the commercialization in the Licensed Territory under the Bayer License Agreement. Under the Bayer Supply Agreement, Bayer shall pay to BridgeBio B.V. a commercial product per unit price equal to the applicable fully burdened manufacturing cost per unit of product, which shall include the cost of the API used to manufacture the product and the packaging price. As of December 31, 2024, there have been no commercial product supply sales to Bayer. The condition for the $75.0 million regulatory-based milestone payment was achieved upon the EC approval of Beyonttra on February 10, 2025. The Company anticipates receiving this milestone payment from Bayer in April 2025.
Read it in 10-K Feb 20, 2025 at sec.gov
RemovedMD&A
Since our inception, we have created wholly-owned subsidiaries or made investments in certain controlled entities, including partially-owned subsidiaries for which we have majority voting interest under the VOE model or for which we are the primary beneficiary under the VIE model, which we refer to collectively as our consolidated entities. Ownership interests in consolidated entities that are held by entities other than us are reported as redeemable convertible noncontrolling interests and noncontrolling interests in our consolidated balance sheets. Losses attributed to redeemable convertible noncontrolling interests and noncontrolling interests are reported separately in our consolidated statements of operations.
Read it in 10-K Feb 20, 2025 at sec.gov
RemovedMD&A
We have included our financial results for 2024 compared to 2023. Our financial results for 2023 compared to 2022 can be found in Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission (the “SEC”), on February 22, 2024 and is incorporated herein by reference.
Read it in 10-K Feb 20, 2025 at sec.gov
RemovedMD&A
The results of operations for the years ended December 31, 2024 and 2023 are not necessarily indicative of the results to be expected for the year ending December 31, 2025 or for any other future annual or interim period.
Read it in 10-K Feb 20, 2025 at sec.gov
RemovedMD&A
Under the terms of the Amended Financing Agreement, the Company is required to deposit 75% of proceeds, net of certain permitted costs, received from certain asset sale transactions into an escrow account to be controlled by the Administrative Agent. During the three months ended June 30, 2024, we received $235.0 million in aggregate from Bayer and Kyowa Kirin, and deposited net proceeds of $159.3 million into the escrow accounts, which was classified as “Restricted cash” on the consolidated balance sheet. Furthermore, under the terms of Amended Financing Agreement, between June 20, 2024 and through the earlier of the FDA approval date or November 30, 2024, the Company was able to request a release of funds in an aggregate amount not to exceed 50% of the original net cash proceeds received from asset sale transactions. During the three months ended June 30, 2024, $20.0 million was released from the escrow accounts. Following the FDA approval of Attruby in November 2024 and receipt of consent from the lenders, the remaining $139.3 million was released from the escrow accounts and classified as cash on the consolidated balance sheet.
Read it in 10-K Feb 20, 2025 at sec.gov
RemovedMD&A
Restricted cash as of December 31, 2023 primarily represents funds in a controlled account that was established in connection with the Loan and Security Agreement (“Amended Loan Agreement”) that is described in Note 9. The use of such non-interest-bearing cash was restricted per the terms of the underlying amended loan agreement and was to be used solely for certain research and development expenses directly attributable to the performance of obligations associated with the Navire-BMS License Agreement, which is further described in Note 11. Upon the termination of the Amended Loan Agreement and full repayment of the term loan in January 2024 (refer to Note 9 for details), the non-interest-bearing cash was no longer restricted.
Read it in 10-K Feb 20, 2025 at sec.gov
RemovedMD&A
On January 17, 2024, we paid our outstanding term loan principal balance under our Amended Loan Agreement with the proceeds from the Amended Financing Agreement plus additional cash from our operations. Under the Amended Financing Agreement, we were extended a senior secured credit facility of $450.0 million in an aggregate principal amount for the Initial Term Loan, which is subject to variable interest rates. As a result of the variable interest rates under our Amended Financing Agreement and Funding Agreement we expect our interest expense will continue to fluctuate in the future. Refer to the Liquidity and Capital Resources section below and Note 9 for details regarding the Term Loan and the Amended Financing Agreement.
Read it in 10-K Feb 20, 2025 at sec.gov
RemovedMD&A
On January 17, 2024, we entered into the Financing Agreement with certain of our subsidiaries party thereto as guarantors, the Lenders and the Administrative Agent, which was amended on February 12, 2024.
Read it in 10-K Feb 20, 2025 at sec.gov
RewordedMD&A
Year Years Ended December 31, 2025 2024 2023 (in thousands) Revenue Total revenues, net $ 502,076 $221,902 $9,303 Cost Total cost of revenue 3,878 2,446 revenues $ 20,962 $3,878 Research and development 506,461 455,711 $ 451,953 $506,461 Selling, general and administrative 288,931 150,590 $ 531,225 $288,931 Restructuring, impairment impairment, and related charges 15,605 7,926 $ 21,347 $15,605 Loss from operations (592,973) (607,370) $ (523,411) $(592,973) Interest income 17,249 18,038 $ 19,854 $17,249 Interest expense (99,290) (81,289) $ (53,103) $(90,991) Noncash interest expense on deferred royalty obligations (1) $ (125,138) $(8,299) Gain on deconsolidation of subsidiaries 178,321 $ — $178,321 Loss on extinguishment extinguishments of debt (26,590) — $ (21,155) $(26,590) Net loss from equity method investments (31,183) — $ (72,608) $(31,183) Other income, net $ 43,058 $12,272 Provision for income (expense), net 12,272 17,370 Income tax expense 1,153 — taxes $ 435 $1,153 Net loss (543,347) (653,251) $ (732,938) $(543,347) Net loss attributable to redeemable convertible noncontrolling 7,585 10,049 interests and $ 8,007 $7,585 noncontrolling interests Net loss attributable to common stockholders of BridgeBio (535,762) (643,202) $ (724,931) $(535,762)
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
Net cash used in operating activities was $520.7 million in 2024, consisting primarily of our net loss of $543.3 million; adjusted The adjustments for non-cash noncash items totaling $9.4 million, which million primarily includes included a gain of $178.3 million from the deconsolidation of subsidiaries, and a net gain of $8.1 million from investment in equity securities, and securities; partially offset by $95.8 million in stock-based compensation expense, $31.2 million net loss from equity method investments, $26.6 million in loss on extinguishment of debt from the repayment of the term loan under the Amended Loan Agreement, $15.8 $8.3 million in noncash interest expense on deferred royalty obligations, $7.5 million in accretion of debt, and $6.1 million in depreciation and amortization; and a $32.0 million net cash inflow related to changes in operating assets and liabilities. amortization.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
On January 17, 2024, we entered into a Financing Agreement with each of the guarantors, which was amended on February 12, 2024 (the “Financing Agreement”) and June 20, 2024 (the Financing Agreement, as amended by the Second Amendment, the “Amended Financing Agreement”), with certain of our subsidiaries party thereto as guarantors, the lenders party thereto (the “Lenders”) and Blue Owl Capital Corporation, as administrative agent for the Lenders (the “Administrative Agent”), which was amended on February 12, 2024 and June 20, 2024 (the Financing Agreement, as amended by the second amendment, the “Amended Financing Agreement”). Agent”).
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
In the event that a change in of control (as customarily defined in the Funding Agreement) occurs on or after the effective date of the Funding Agreement Agreement, the Purchasers may elect to require the Seller Parties to make the Buy-Out Payment and prior to FDA approval of acoramidis, either party may terminate the Funding Agreement and will be terminated upon payment in-full of the Seller Parties shall make a one-time payment of $25.0 million (in Parties’ obligations under the aggregate) to Funding Agreement (including the Purchasers. Buy-Out Payment and all reimbursable expenses).
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
Our short-term and long-term liquidity requirements include contractual payments related to our 2033 Notes (refer to Note 19 to our consolidated financial statements), 2031 Notes, 2029 Notes, and 2027 Notes and term loan (refer to Note 9 to our consolidated financial statements, accounts payable, accrued liabilities), statements), our deferred royalty obligation obligations, net under the Funding Agreement and Royalty Purchase Agreement (refer to Note 10 to our consolidated financial statements), as well as obligations under our real estate leases (refer to Note 14 13 to our consolidated financial statements) statements), accounts payable, accrued liabilities and the remaining liabilities under our restructuring initiative (refer to Note 17 16 to our consolidated financial statements).
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
In consideration for the license grant, the Seller Parties received are entitled to receive an upfront payment of $135.0 million million, which was received in full in May 2024, and will be eligible to receive up to $150.0 million in regulatory and sales milestone payments through 2026 (of which $75.0 million is for a regulatory milestone dependent of $75.0 million was achieved in February 2025 upon EC approval of acoramidis on or before December 31, under the brand name Beyonttra and received in April 2025), and additional payments up to $450.0 million subject to the achievement of certain sales milestones.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
Year Years Ended December 31, 2025 2024 2023 (in thousands) Acoramidis for the treatment of ATTR-CM and primary prevention in $ 116,844 $ 164,782 $ 101,041 asymptomatic carriers of a pathogenic TTR variant Infigratinib for achondroplasia and hypochondroplasia 122,685 91,869 63,239 BBP-418 (ribitol) for LGMD2I/R9 56,008 40,220 33,903 Encaleret for ADH1 59,955 49,091 44,773 Other development programs 22,703 71,732 82,165 Other research programs 73,758 88,767 130,590 Total $ 451,953 $ 506,461 $ 455,711
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
In consideration for the license grant, the Seller Parties received an upfront payment of $135.0 million in May 2024 and will be eligible to receive up to $150.0 million in regulatory and sales milestone payments through 2026 (of which $75.0 million is for a regulatory milestone dependent of $75.0 million was achieved and recognized as license and services revenue in February 2025 upon EC approval of acoramidis on or before December 31, under the brand name Beyonttra and received in April 2025), and additional payments up to $450.0 million subject to the achievement of certain sales milestones.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
Under the Eidos-Alexion License Agreement, Eidos received an upfront nonrefundable payment of $25.0 million million, and is eligible to receive in June 2025, Eidos received a regulatory milestone payment of $30.0 million in regulatory milestone payments and royalties in following pricing approval from the low-teens based on net sales of acoramidis National Health Insurance in Japan.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
Interest expense consists primarily of interest expense incurred under our 2031 Notes issued in February 2025, our 2029 Notes issued in January 2021, and our 2027 Notes issued in March 2020, our term loan under the Amended Financing Agreement, our term loan under the Amended Loan Agreement, and our deferred royalty obligation under the Funding Agreement. 2020.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
On January 17, 2024, the Company we and its subsidiaries Eidos Therapeutics, Inc., Eidos, BridgeBio Europe B.V. and BridgeBio International GmbH (collectively, the “Seller Parties”) entered into the a Funding Agreement (the “Funding Agreement”) with the Purchasers, LSI Financing 1 Designated Activity Company and Alter Domus (US) LLC, as the collateral agent. CPPIB Credit Europe S.à r.l.
Read it in 10-K Feb 24, 2026 at sec.gov
RewordedMD&A
As of December 31, 2024, 2025, we had cash and cash, cash equivalents and marketable securities of $681.1 million and restricted cash of $0.1 $587.5 million, compared to cash and cash equivalents of $375.9 million, restricted cash of $16.7 million and investment in equity securities of $58.9 $681.1 million as of December 31, 2023. 2024.
Read it in 10-K Feb 24, 2026 at sec.gov

Sources

The two latest 10-Ks on EDGAR, section by section. Each change links to the text at sec.gov.

Also

New risk factors: paragraphs with nothing like them last year, quoted in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/BBIO/export.csv") into a cell.

Next:Related parties
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.